CSL Behring's existing Broadmeadows facility in Melbourne.

CSL Subsidiary Seqirus is seeking security and CCTV solutions for its greenfield $900 million Banksia Project, a new biopharmaceutical facility being constructed by BESIX Watpac in Melbourne.

The scope of works includes an integrated electronic security system including access control, alarms, automation, monitoring, CCTV and an integrated security management solution.

Project Banksia involves the design, construction, validation and registration of a new state-of-the-art biopharmaceutical facility, which will use innovative cell-based technology to produce influenza vaccines for use in both influenza pandemics and seasonal vaccination programs. This will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere. The facility will also manufacture Seqirus’ proprietary adjuvant MF59 and will produce unique products important to Australia’s public health needs – including antivenom for Australian snakes, spiders and marine creatures, and the world’s only human vaccine for Q-Fever.

Lead contractor, BESIX Watpac, is a wholly owned subsidiary of BESIX Group, and specialises in complex construction across all sectors, including infrastructure and marine works. The greenfield project includes site utilities and amenity to support the manufacturing operation, including black and clean utilities, warehousing, quality control laboratories, administration, cafeteria, car parking, etc, with a completion date of mid-2026.

This tender closes July 30 – you can find out more here.